- Home
- GIX vs PBYI Comparison
GIX vs PBYI Comparison
Compare GIX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GIX | PBYI |
|---|---|---|
| Founded | 2025 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.4M | 413.3M |
| IPO Year | 2025 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GIX | PBYI |
|---|---|---|
| Price | $9.99 | $9.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.3K | ★ 297.9K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $118.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.80 | $4.30 |
| 52 Week High | $9.99 | $9.74 |
Technical Indicators
Market Signals| Indicator | GIX | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 74.64 | 61.10 |
| Support Level | $9.92 | $7.56 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.36 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 100.00 | 76.21 |
Price Performance
Historical ComparisonAbout GIX GigCapital9 Corp. Class A Ordinary Share
GigCapital9 Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.